• Icon International Neuroendocrine Cancer Alliance

  • Mail: post@incalliance.org


cycling 3
Cycling for Net

Our Cycling Team will  leave Paris on 24 June, to arrive in Winchester on 28 June.  Professor Ramage will join our team, composed mainly of patients and carers, and he will accompany them to Winchester. In May 2015, members of our Association APTED (Association de Patients porteurs de Tumeurs Endocrines Diverses) met in Paris to…

Read More
UK - sign the petition web
INCA support the NET Cancer community in UK

  INCA Strongly Supports the NET Community in the UK in its efforts to access to PRRT INCA strongly supports the neuroendocrine (NET) cancer community in the United Kingdom in its efforts to alleviate the devastating side effect of removing an outstanding, life changing treatment, Peptide Receptor Radionuclide Therapy (PRRT) Lutetium-177 DOTA Octreotate, for patients with progressive, inoperable neuroendocrine…

Read More
Epidemiology-infographic Header INCA
Epidemiology for NET Cancer

Epidemiology is the study and analysis of the patterns, causes, and effects of health and disease conditions in defined populations. It is the cornerstone of public health, and shapes policy decisions and evidence-based practice by identifying risk factors for disease and targets for preventive healthcare. Infographics about NET cancers   There are several sources for our…

Read More
Teodora at esmo 900
INCA Appoints First Executive Director

PRESS RELEASE,  March 2, 2016   The International Neuroendocrine Cancer Alliance (INCA) Appoints First Executive Director, Teodora Kolarova     Ron Hollander, President of the International Neuroendocrine Cancer Alliance (INCA) and Executive Director of the NET Research Foundation (USA), is pleased to announce the appointment of Teodora Kolarova of Bulgaria as INCA’s first Executive Director. Ms. Kolarova…

Read More
INCA bro-ncd
INCA Brochure

“It is the passion to change things for the betterment of neuroendocrine cancer patients that drives us forward as a deeply committed team, to unite patient advocates from around the globe in this effort.” The INCA Team. Read our new brochure here ....                     The International…

Read More
ron1 web


Blog post by Ron Hollander.

The International Neuroendocrine Cancer Alliance (INCA) held its annual  Summit and Member meeting in Oxford, England. The assembled representatives from NET groups in 18 nations focused on ways to spread awareness, assist NET groups, and support research for NET patients worldwide. 

INCA summit Oxford
(L-R) INCA Secretary Jo Grey (UK) – Association for Multiple Endocrine Neoplasia Disorders (AMEND); CFCF Funded Researcher Tim Meyer, MD, PhD – UCL Cancer Institute, University College London; INCA President Teodora Kolarova (Bulgaria) – APOZ & Friends; Ron Hollander – CFCF Executive Director; Josh Mailman – President of NorCal CarciNET Community; Yoshiyuki Majima (Japan) – PanCan

Read More
bill1 web
Good news for NET Cancer


Blog post by Bill Claxton.

Good news from Vienna, ECC 2015, the European Cancer Congress,
announced by Philippe Ruszniewski, MD, head of gastroenterology and pancreatology at Beaujon Hospital, in Clichy, France.

“Treatment with the novel peptide receptor radionuclide therapy (PRRT) Lutathera significantly increased progression-free survival (PFS) over octreotide LAR (Sandostatin) in patients with advanced midgut neuroendocrine tumors (NETs), according to findings from the phase III NETTER-1 trial presented at the 2015 European Cancer Congress.”
Medical abstract is here (www.europeancancercongress) and a press release is here (www.onclive.com).


Read More
survey time
Quality of life – Survey

  Results from the survey “Quality-of-life”, patients with neuroendocrine tumors (NET)1. The survey gathered information on the NET patient experience, including diagnosis, disease impact and management, quality of life, and knowledge and awareness levels.   Quality of life results Multidisciplinary approach Challenges of diagnosing   “This is the first time the NET patient experience has…

Read More
ENETS-Leyden web2
Quality of life – at ENETS

  Results from the global survey “Quality-of-life”, patients with neuroendocrine tumors (NET)1. Presented at ENETS, European Neuroendocrine Tumor Society, in Barcelona. NET Cancer patient experience, including diagnosis, disease impact and management, quality of life, and knowledge and awareness levels.                 Patient Perspective  Time to Diagnosis  Multidisciplinary team  Patient Experience…

Read More
survey iweb1
Global NET patient survey

The International Neuroendocrine Cancer Alliance (INCA) and Novartis presents the quality-of-life results from the first global survey of patients with neuroendocrine tumors (NETs), a rare type of cancer1.

Nearly 2,000 patients from 12 countries completed the survey, which was a collaborative effort between INCA and Novartis. The results were presented at a medical meeting and provide compelling data documenting the impact of NETs on people living with this disease1. These quality-of-life findings are the first in a series of results from the survey being released in conjunction with Worldwide NET Cancer Awareness Day (WNCAD), November 10.

Read More
Copyright © 2015 International Neuroendocrine Cancer Alliance. All right reserved.
Make a Donation
Paybal button